Flavopiridol: where do we stand in chronic lymphocytic leukemia? (Q44690650)

5 December 2017

Flavopiridol: where do we stand in chronic lymphocytic leukemia? (English)

1 reference

5 December 2017

0 references

Lin TS

1

1 reference

PubMed ID

14671637

5 December 2017

Porcu P

series ordinal

2

1 reference

PubMed ID

14671637

5 December 2017

language of work or name

1 reference

1 February 2004

1 reference

5 December 2017

1 reference

5 December 2017

18

1 reference

5 December 2017

243-246

1 reference

5 December 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403237

5 December 2017

0 references

cites work

Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Ionizing radiation activates the ATM kinase throughout the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Activation of the ATM kinase by ionizing radiation and phosphorylation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Protective roles for ATM in cellular response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

The controlling role of ATM in homologous recombinational repair of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

7 January 2021

Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

7 January 2021

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403237

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403237

1 reference

5 December 2017

1 reference

PubMed ID

14671637